Gilead 4Q Revenues:  $5.9 billion (-19%) 4Q Loss: $3.8 billion (earnings were $3.1 billion 4Q16) FY Revenues: $26.1 billion (-14%) FY Earnings: $4.6 billion (-66%) Comments: Antiviral product sales, which include HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.2 billion, down 21%. Tenofovir alafenamide (TAF)-based products performed well in the quarter. Genvoya sales were $1.1 billion, up 88%. Descovy sales were $365 million, up 145% and Odefsey sales were $32...